Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Impax Asset Management Group plc

Impax Asset Management Group plc lessened its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) by 61.8% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 100,000 shares of the company's stock after selling 161,599 shares during the period. Impax Asset Management Group plc owned approximately 0.10% of Neurocrine Biosciences worth $11,060,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. grew its holdings in shares of Neurocrine Biosciences by 2.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 762,557 shares of the company's stock valued at $104,089,000 after buying an additional 15,266 shares during the last quarter. Avantax Advisory Services Inc. grew its stake in Neurocrine Biosciences by 11.4% during the 4th quarter. Avantax Advisory Services Inc. now owns 2,895 shares of the company's stock valued at $395,000 after purchasing an additional 297 shares during the last quarter. Smartleaf Asset Management LLC grew its stake in Neurocrine Biosciences by 37.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 538 shares of the company's stock valued at $74,000 after purchasing an additional 146 shares during the last quarter. Corient Private Wealth LLC grew its stake in Neurocrine Biosciences by 64.0% during the 4th quarter. Corient Private Wealth LLC now owns 7,927 shares of the company's stock valued at $1,082,000 after purchasing an additional 3,094 shares during the last quarter. Finally, B. Metzler seel. Sohn & Co. AG grew its stake in Neurocrine Biosciences by 5.1% during the 4th quarter. B. Metzler seel. Sohn & Co. AG now owns 5,044 shares of the company's stock valued at $689,000 after purchasing an additional 245 shares during the last quarter. Hedge funds and other institutional investors own 92.59% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on NBIX. Guggenheim upped their target price on Neurocrine Biosciences from $155.00 to $165.00 and gave the company a "buy" rating in a research report on Tuesday, May 6th. Needham & Company LLC increased their price objective on shares of Neurocrine Biosciences from $138.00 to $139.00 and gave the stock a "buy" rating in a research note on Tuesday, May 6th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $145.00 price objective on shares of Neurocrine Biosciences in a research note on Monday, June 2nd. Wall Street Zen lowered shares of Neurocrine Biosciences from a "strong-buy" rating to a "buy" rating in a research note on Thursday, March 20th. Finally, HC Wainwright cut their price target on Neurocrine Biosciences from $185.00 to $168.00 and set a "buy" rating on the stock in a research report on Tuesday, April 22nd. Three analysts have rated the stock with a hold rating and twenty have assigned a buy rating to the stock. According to data from MarketBeat, Neurocrine Biosciences has a consensus rating of "Moderate Buy" and an average target price of $162.00.

Neurocrine Biosciences Stock Performance

Neurocrine Biosciences stock traded down $1.37 during trading on Friday, reaching $128.04. The company had a trading volume of 387,387 shares, compared to its average volume of 1,143,644. The firm's 50-day simple moving average is $121.77 and its 200 day simple moving average is $121.68. Neurocrine Biosciences, Inc. has a 1-year low of $84.23 and a 1-year high of $157.98. The firm has a market capitalization of $12.67 billion, a PE ratio of 43.40, a price-to-earnings-growth ratio of 1.32 and a beta of 0.24.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 12.68% and a return on equity of 11.81%. The company had revenue of $572.60 million during the quarter, compared to analyst estimates of $587.06 million. During the same quarter last year, the business earned $1.20 EPS. The firm's revenue for the quarter was up 11.1% compared to the same quarter last year. Analysts anticipate that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Insider Activity

In related news, Director William H. Rastetter sold 30,000 shares of Neurocrine Biosciences stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $110.20, for a total value of $3,306,000.00. Following the sale, the director directly owned 37,491 shares in the company, valued at approximately $4,131,508.20. The trade was a 44.45% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director Kevin Charles Gorman sold 9,613 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The stock was sold at an average price of $120.38, for a total value of $1,157,212.94. Following the sale, the director owned 514,596 shares of the company's stock, valued at $61,947,066.48. The trade was a 1.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 4.80% of the company's stock.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.